276 related articles for article (PubMed ID: 19680291)
1. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
Hirsch FR
Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
[TBL] [Abstract][Full Text] [Related]
2. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
3. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
Burris HA
Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
[TBL] [Abstract][Full Text] [Related]
4. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
6. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Batus M; Fidler MJ; Bonomi PD
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
8. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
Wong KK
Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
Eberhard DA; Giaccone G; Johnson BE;
J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
[TBL] [Abstract][Full Text] [Related]
11. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; Onn A; Ciardiello F
Cancer; 2004 Oct; 101(8):1733-44. PubMed ID: 15386339
[TBL] [Abstract][Full Text] [Related]
12. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
13. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Sangha R; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
16. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
17. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Thatcher N
Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
19. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
20. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
Oxnard GR
Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
